Kornimate/medical-research-clean huggingface dataset:
comparison of drug eluting and bare metal stents with or without abciximab in st elevation myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the debater study is designed to determine the superiority of abciximab over no abciximab and to determine the superiority of drug eluting stents over bare metal stents in patients with acute myocardial infarction who undergo percutaneous coronary intervention.

in patients with acute myocardial infarction primary pci without prior thrombolytic therapy, is the treatment of choice. the recommendation for routine stenting in pci is based on 4 studies that have demonstrated the usefulness of bare metal stents in patients with stemi. however this recommendation cannot be extrapolated (yet) to the use of drug eluting stents. although des have been used widely in unstable angina and in acute myocardial infarction, to date there are no evidence-based recommendations to support the routine use of des in stemi. gpi have been studied extensively in patients with non-stsegment elevation myocardial infarctions (nstemi) with planned or performed pci. in stemi tirofiban and and eptifibatide are less well investigated, and only abciximab is recommended in primary pci, but the long term benefits require more investigation. in pci randomized controlled clinical trials (rct's) abciximab consistently showed a significant reduction in the rate of myocardial infarction and the need for urgent revascularization. abciximab has been evaluated in 5 rct's in association with primary pci. the pooled analysis for the clinical outcome at 30 days, demonstrate a significant reduction of death, re- infarction and target vessel revascularization (tvr), mainly due to a reduction of repeat intervention. the long-term benefits require more investigation. the debater trial is designed to answer the questions about the need for abciximab and about the use of des in primary pci.

Eligibility criteria:
inclusion criteria: * stemi ≤ 12 hours (or stemi equivalent). * no contra - indications for primary pci. * no contra - indications for abciximab. * informed consent from the patient. exclusion criteria: * contra - indication for primary pci: history of peripheral/coronary artery disease that is inaccessible for angiography or pci. * contra - indications for gpi: ongoing bleeding, bleeding diathesis, cerebrovascular accident \ 1.5, severe hepatic dysfunction * contra - indications for clopidogrel: * severe liver dysfunction, pathological bleeding disorders such as peptic ulcer or intracranial bleeding. * thrombolytic therapy \< 24 hours. * therapy with gpi \< 24 hours. * anticoagulation therapy. * co - morbid conditions with a predictable fatal outcome in the short run. * no informed consent: refusal, coma, artificial respiration, impaired mentation.

Keywords: stemi des bms abciximab
stop: venous thromboembolism screening in the trauma population

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Trauma, Multiple

Summary: this is a prospective, randomized vanguard trial of trauma patients admitted to the trauma surgery service at intermountain medical center who are deemed to be at high risk for venous thromboembolism. once identified and enrolled, subjects will be randomized to receive bilateral lower extremity duplex ultrasound surveillance versus no surveillance. the study will compare the two groups with regard to deep vein thrombosis, pulmonary embolism, and major and clinically relevant bleeding episode rates, both during the index hospitalization and at 90 days post-discharge.


Eligibility criteria:
inclusion criteria: 1. inpatient status on intermountain medical center (imc) trauma surgery service, admitted within 24 hours of injury. 2. age ≥18 at the time of injury 3. meets the definition of high-risk for vte according to current imc trauma service guidelines exclusion criteria: 1. patient age \<18 years at the time of admission to the hospital 2. pregnancy 3. prisoners 4. patients with a life expectancy of less than 30 days 5. patients with a known hypercoagulable state including: * factor v leiden * protein c and s deficiencies * dysfibrogenemia of any sort * active cancer * antiphospholipid antibody syndrome * history of dvt or pe within past 6 months * myeloproliferative disorders 6. patients on therapeutic anticoagulation who do not have their agent held upon admission to the hospital. 7. patient elects to opt-out of the study

Keywords: duplex ultrasound trauma venous thromboembolism prevention
clinical performance of masimo invsensor00057 for atrial fibrillation detection

Conditions: Healthy

Summary: this study is designed to validate the performance of masimo invsensor00057 in detecting atrial fibrillation. the noninvasive ecg measurements will be compared to results obtained from an fda-cleared ecg monitor.


Eligibility criteria:
inclusion criteria: * the subject is 18 to 80 years of age. * subject can read and communicate in english. * subject's cardiac rhythm shall be normal sinus rhythm or atrial fibrillation (afib). this determination will be made using fda cleared 3-lead ecg which will label subject's cardiac rhythm as such. exclusion criteria: * subject has open wounds, inflamed tattoos or piercings on the area of device placement, and/or has any visible healing wounds that the investigator and/or medical professional determines may place them at an increased risk for participation. * subject has any medical condition which in the judgment of the investigator and/or study staff, renders them ineligible for participation in this study or subject is deemed ineligible by the discretion of the investigator/study staff.
new methods to diagnose constrictive pericarditis

Conditions: Constrictive Pericarditis

Summary: until now, diagnosis of constriction was based on pressure changes of ventricle by conventional pressure-wide hemodynamic evaluation but not on ventricular volume change. this study will provide answers to persisting questions about volume changes during respiration in patients with constrictive pericarditis by directly measuring both right and left ventricular volume.


Eligibility criteria:
subjects referred for right and left heart catheterization will be eligible.
in vivo molecular imaging predicts therapeutic response in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: molecular imaging with infliximab antibody with fitc has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.


Eligibility criteria:
inclusion criteria: * patients with active ulcerative colitis will receive infliximab antibody therapy. exclusion criteria: * patients with impaired blood clotting. * patients with short bowel syndrome. * patients during the pregnancy and lactation period. * patients received enema therapy within 1 month before inclusion in the study, or had anti-tnf therapy within the last 12 months. * patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit. * patients with moderate to severe heart failure, active tuberculosis or acute infections.
safety of exercise and high-dose salbutamol in patients with chronic obstructive pulmonary disease (copd) receiving therapeutic doses of indacaterol (qab 149) and salmeterol

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (copd) receiving therapeutic doses of indacaterol, salmeterol and placebo.


Eligibility criteria:
inclusion criteria: * patients between 40 and 75 years of age diagnosed with chronic obstructive pulmonary disease (copd). female patients must be surgically sterilized, postmenopausal or using a double-barrier method of contraception. * body mass index (bmi) must be within the range of 18 to 32. exclusion criteria: * participation in any clinical investigation with experimental drug therapy within four weeks prior to dosing or longer as required by local regulation. * donation or loss of 400 ml or more of blood within two months prior to dosing. * significant illness (other than respiratory) within two weeks prior to dosing. * a past medical history of, or a family history (grandparents, parents and siblings) of a prolonged qt-interval syndrome or a prolonged qt-interval at screening. * any clinically significant medical abnormalities (excluding copd) limiting ability to perform standardized exercise protocol on cycle ergometer will exclude the patient. for example, arthritis. * history of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). * a known hypersensitivity to the study drug or drugs similar to the study drug. * history of immunocompromise, including a positive hiv, hepatitis b or c test result. * history of drug or alcohol abuse within the 12 months prior to dosing * any conditions that in the opinion of the investigator may compromise patient safety, interfere with evaluations, or preclude the completion of the trial. other protocol-defined inclusion/exclusion criteria may apply

Keywords: copd cycle ergometry exercise testing spirometry cardiovascular salbutamol indacaterol chronic obstructive pulmonary disease
wheelchair skills training for people with arsacs and dm1

Conditions: Wheelchair Mobility; Manual Wheelchair Skills Training; ARSACS; Myotonic Dystrophy Type 1

Summary: wheelchairs (wc) are often provided to people with arsacs and md1 when they are not able to walk anymore. however, giving someone a mwc alone does not guarantee they will use it safely or properly. many people who use wc need help from others to get around and they can not always do the things they like to do. this can lead to isolation, stress, and reduced quality of life. in addition, poor use of a mwc could lead to accidents and injuries. our team recently showed that people with arsacs have lower mwc skills than other adults who use mwc, and that teaching mwc skills to people with arsacs seems to work. now we are ready to test the program with more people with arsacs and md1 to see how it can improve mwc mobility and confidence. we also want to hear about people's expectations and experiences with mwc training. people who take part in research will answer questions before and after wc training, and we will follow up with them 3 months later to ask again about their wc use. this projects directly adresses the mobility needs of people with arsacs and md1 who use mwc. our results may improve how therapists provide training for mwc use, which may improve mobility, participation, and quality of life for people with arsacs and md1. learning just one mwc skill could be life-changing. it could mean the difference between leaving the house or not, which could impact the ability to shop for groceries, see friends, or to have a job.


Eligibility criteria:
inclusion criteria: * ≥18 years of age, have a diagnosis of arsacs or dm1, and use a manual wc for mobility (≥3 times/week for ≥8 hours/week). exclusion criteria: * anticipate a health condition or procedure that contraindicates training (e.g., surgery); or concurrently or planning to receive wc training during the study.
dynamic acl brace: in vivo kinematics

Conditions: ACL Injury; ACL - Anterior Cruciate Ligament Rupture; ACL; ACL - Anterior Cruciate Ligament Deficiency

Summary: the purpose of this study is to evaluate the effect of the össur rebound dynamic acl brace on knee kinematics evaluated using dynamic stereo x-ray (dsx) imaging during functional activities. brace performance will be evaluated before and after acl reconstruction.


Eligibility criteria:
inclusion criteria: * unilateral, complete acl (anterior cruciate ligament) ruptures (must be documented by prior mri) * no other concomitant lower extremity injuries and an uninjured contralateral limb * acute acl tears that will be scheduled for acl reconstruction with dr. robert f. laprade * minimal swelling and pain * able and willing to perform the required study activities exclusion criteria: * previous surgery or significant injury to either knee * relevant surgery, procedure, injury, or condition in the past two years which may affect knee pain or general movement patterns on either side * diagnosis of osteoarthritis, rheumatoid conditions, cancers, or other conditions which may affect musculoskeletal health * women who are pregnant, or trying/planning to become pregnant during the next 10 months * known balance or vestibular disorders * persons with a history of significant radiation exposure, whether occupational or medical in nature (anyone with a history of medical radiation therapy, for cancer or other conditions, is excluded from the study. those who have an annual occupational radiation exposure greater than 25msv may not enroll.) * persons with a pacemaker, hearing aid, aneurysm clip or artificial heart valve, or other forms of loose metal implants * initial mri exclusion criteria (assessed by clinical mri obtained as standard of care at time of acl injury diagnosis): concomitant injury, multi-ligamentous injury, significant meniscal damage * allergy or sensitivity to silver or latex * adults lacking capacity to consent for themselves post-op visit exclusion criteria * participants who do not pass their return-to-sport test within 7-9 months of acl-reconstruction surgery will be excluded from the second phase of testing. * participants who no longer pass the mri screening at the time of phase 2 testing (for example, who have a new loose metal implant), will be excluded from the mri portion of the testing only.
wrist position sense in individuals with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: no study has been found examining the effect of wrist position sense on manual dexterity in individuals with multiple sclerosis.the purpose of this study is to examine the effect of wrist position sense on manual dexterity of the hand.

multiple sclerosis is a chronic demyelinating disease of the central nervous system that occurs in young adults and usually progresses with attacks and remissions. as the disease progresses, symptoms such as fatigue, muscle weakness, loss of balance, loss of sensation, spasticity, visual disturbances and bladder dysfunction are observed. in addition to these symptoms, hand functions may be affected even in the early stages of the disease. appropriate motor control and mobility skills are required to perform manual dexterity effectively. joint stabilization and perception of the joint's position and movement in space are needed for motor control of hand functions. in this process, position sense signals contribute significantly to the target localization and performance of the hand. position sense signals must be constantly updated for the coordination and integration of hand position during manual activities such as holding or grasping an object. this is possible with a healthy sense of position. although it is known that position sense is affected in ms patients, no study has been found examining the effect of wrist position sense on manual dexterity. the purpose of this study is to examine the effect of wrist position sense on hand dexterity. patients' manual dexterity will be evaluated using the purdue pegboard test, and wrist position sense will be evaluated using the k-force sens® electrogoniometer.

Eligibility criteria:
inclusion criteria: * patient group: * disability score (edss: expanded disability status scale) should be between 0-3. * being between the ages of 18-50 * not having had an attack in the last 3 months * scoring 24 points or above on the mini-mental state examination * patients diagnosed with relapsing-remitting ms with a disease duration of at least 2 years * patients without spasticity according to mas control group: * volunteers in a similar age range who agreed to participate in the study * being between the ages of 18-50 exclusion criteria: * patient group: * presence of diagnosed visual impairment * having other chronic diseases not related to ms * having any orthopedic, neurological, rheumatological or metabolic diagnosis that causes upper extremity involvement * history of hand and upper extremity disorders, peripheral nerve disorders, and medical or psychiatric disorders that may significantly affect cognitive function * presence of wrist joint range of motion limitation control group: * having any orthopedic, neurological, rheumatological or metabolic diagnosis that causes upper extremity involvement * history of hand and upper extremity disorders, peripheral nerve disorders, and medical or psychiatric disorders that may significantly affect cognitive function * presence of wrist joint range of motion limitation

Keywords: multiple sclerosis manual dexterity position sense
understanding the importance of plasticity in the brain mechanisms of dyspnoea perception

Conditions: Chronic Obstructive Pulmonary Disease

Summary: dyspnoea is the uncomfortable shortness of breath that debilitates millions of patients with lung disease, heart failure and cancer. it is often very difficult to treat. the sensations of dyspnoea are processed in the brain, and we believe that psychological factors modify and amplify these sensations, frequently exacerbating symptoms. this study aims to identify the importance of learning in the brain mechanisms of dyspnoea by investigating a cohort of patients with chronic breathlessness undergoing pulmonary rehabilitation . pulmonary rehabilitation is a six-week course of exercise, education and group therapy that improves dyspnoea but does not improve lung function. this leads us to hypothesise that some of the beneficial effects of pr maybe due to changes in brain processing, potentially relating to a learning effect. therefore to probe whether learning is important in the beneficial effects of pulmonary rehabilitation, we intend to modify learning with the drug d-cycloserine. d-cycloserine is an antibiotic that enhances learning due to its effects at n-methyl d-aspartate (nmda) receptors in the hippocampus. our previous study in a similar group of patients demonstrated the importance of the hippocampus in breathlessness perception, and we now wish to investigate this in more depth. the study involves collecting physiological, psychological and clinical measures on in conjunction with brain scanning, before, during and once after pulmonary rehabilitation. subjects will either receive d-cyloserine or placebo before the first four pulmonary rehabilitation sessions.


Eligibility criteria:
inclusion criteria: * males and females with chronic lung disease, aged between 45 and 85 years old who have been referred for pulmonary rehabilitation. * the subject is able and willing to give fully informed consent. exclusion criteria: any of the commonly accepted contraindications to mri scanning, for example, severe claustrophobia, presence of metallic implants, a pacemaker etc. * pregnancy. the risk to foetus of radiofrequency energy of the mri scan is unknown. * inadequate understanding of verbal and written information in english, sufficient to complete an mri safety screening. * unable to lie flat and still for 1/2 hour * requirements for oxygen therapy * significant cardiac, neurological, psychiatric or metabolic disease * contra-indications to d-cycloserine: alcoholism, known hypersensitivity, severe renal failure * regular therapy with prescribed opioid analgesics * antidepressant therapy (this may alter hippocampal plasticity) * previous pulmonary rehabilitation (because the learning may be different on repeat pulmonary rehabilitation treatments)

Keywords: dyspnea fmri d-cycloserine
non pharmacological treatment in alzheimer's disease and associated disorders

Conditions: Alzheimer's Disease

Summary: the stim-ehpad study (for stimulation in nursing home) aims to evaluate the short and medium term effectiveness of staff education as a non-pharmacological intervention to manage apathy in older people with a diagnosis of dementia. * primary efficacy criteria: apathy inventory clinician score changes * secondary efficacy criteria: apathy inventory patient and caregiver version changes, observation scale changes, frequency and severity of the other bpsd using the npi, qualitative analysis of the nursing home staff behavioural changes


Eligibility criteria:
inclusion criteria: * patients older than 65 years * a diagnosis of dementia according to the icd 10 criteria * mmse score ≤ 24 * presenting the diagnostic criteria of apathy (cf page ??) * an apathy inventory clinician total score \>3 (with at least a score higher than 1 at one of the 3 dimensions; lack of initiative, lack of interest, emotional blunting) exclusion criteria: * patients more than 65 years * mmse score \> 24
human umbilical cord mesenchymal stem cells transplantation for patients with decompensated liver cirrhosis

Conditions: Liver Cirrhosis

Summary: although liver transplantation provide a option to cure patients suffering with decompensated liver cirrhosis this condition, lack of donors, postoperative complications, especially rejection, and high cost limit its application. bone marrow derived mesenchymal stem cells (bm-mscs) have been shown to replace hepatocytes in injured liver, effectively rescued experimental liver failure and contributed to liver regeneration, which suggest the novel and promising therapeutic strategy in this study, the safety and efficacy of human umbilical cord mesenchymal stem cells (huc-mscs) transplantation for patients with decompensated liver cirrhosis will be evaluated.

to investigate the safety and efficacy of human umbilical cord mesenchymal stem cells transplantation in patients of decompensated liver cirrhosis.

Eligibility criteria:
inclusion criteria: * written informed consent. * aged 18-70 years. * decompensated liver cirrhosis, child-pugh b/c (7-12 points); or meld score≦21. * expecting lifetime is over 2 months. * hepatitis b decompensated liver cirrhosis patients need antiviral therapy. exclusion criteria: * severe drug allergic history or anaphylaxis. * severe problems in other vital organs(e.g. the heart, renal or lungs) * severe problems in psychiatric disease,such as schizophrenia,et al * severe bacteria infection. * malignancies. * alcoholism or drug abuse. * plan to have liver transplantation in 3 months. * pregnancy * candidates who are participating in other study.

Keywords: decompensated liver cirrhosis umbilical cord mesenchymal stem cells